0001144204-18-045633.txt : 20180920 0001144204-18-045633.hdr.sgml : 20180920 20180820172549 ACCESSION NUMBER: 0001144204-18-045633 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20180820 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Synthetic Biologics, Inc. CENTRAL INDEX KEY: 0000894158 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133808303 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 9605 MEDICAL CENTER DRIVE STREET 2: SUITE 270 CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: (734) 332-7800 MAIL ADDRESS: STREET 1: 9605 MEDICAL CENTER DRIVE STREET 2: SUITE 270 CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: ADEONA PHARMACEUTICALS, INC. DATE OF NAME CHANGE: 20081027 FORMER COMPANY: FORMER CONFORMED NAME: PIPEX PHARMACEUTICALS, INC. DATE OF NAME CHANGE: 20061214 FORMER COMPANY: FORMER CONFORMED NAME: SHEFFIELD PHARMACEUTICALS INC DATE OF NAME CHANGE: 19970730 CORRESP 1 filename1.htm

9605 Medical Center Drive, Suite 270
Rockville, Maryland 20850

	August 20, 2018

VIA EDGAR

United States Securities
and Exchange Commission
Division of Corporation Finance

Office of Healthcare & Insurance

100 F Street, NE

Washington, D.C. 20549

Attention:

Ms. Irene Paik

Ms. Christine Westbrook

Re:

Synthetic Biologics, Inc.

Registration Statement on Form S-3

Filed August 1, 2018

File No. 333-226500

Dear Mss. Paik and Westbrook:

Synthetic Biologics, Inc. (the “Company”) hereby requests acceleration of the effective date of the above-referenced Registration Statement on Form S-3 so that it may become effective at 5:00 p.m. (New York City Time) on Wednesday, August 22, 2018, or as soon thereafter as reasonably practicable.

The Company hereby authorizes its legal counsel, Leslie Marlow and/or Patrick Egan of Gracin & Marlow, LLP, to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (516) 496-2223 or (212) 907-6457, or Mr. Egan at (914) 557-5574 with any questions you may have concerning this request, and please notify either of them when this request for acceleration has been granted.

Very truly yours,

SYNTHETIC BIOLOGICS, INC.


By:	/s/ Steven A. Shallcross
	Name: Title:	Steven A. Shallcross Interim Chief Executive Officer and Chief Financial Officer

GRAPHIC 2 syn_logo.jpg GRAPHIC begin 644 syn_logo.jpg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